Hany Zayed, Ph.D. is the head of Data Science Solutions group at Rigel Pharmaceuticals. He has more than 25 years of experience in development of novel treatments. He has special research interest in the development of novel treatments and therapeutics of rare and orphan indications. Prior to joining Rigel, he was the Head of Biometrics at AbbVie Stemcentrx, XOMA and Nektar Therapeutics where he played vital roles in the development and regulatory approval of novel treatments in various therapeutic areas including oncology, hematology and immunology to US and European patients. He received a Ph.D. in Biostatistics in 2001.